Lung Cancer, Non-Small CellNCT06942845
Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study
An observational study of Lung Cancer, Non-Small Cell and Postoperative Cerebral Infarction, run by Xinghua Cheng at 1 site in China.
Trial summary
Lung cancer remains the world's leading cancer in terms of morbidity and mortality, with more than 20 million new cases and 9.7 million deaths annually. Despite improvements in surgical techniques and medical care, the number of elderly people undergoing surgery is gradually increasing, so there are an increasing… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Lung Cancer, Non-Small Cell, Postoperative Cerebral Infarction
- What is being tested?
- non-intervention
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 1 Apr 2025to 1 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: 1. patients with postoperative cerebral infarction in the hospital during the same period of time as the case group 2. hospitalised surgical patients in the same period as the control group. 3. patients who underwent pneumonectomy for lung nodules as the reason for surgery.
Who may be able to join
- Postoperative cerebral infarction
Who cannot join
- No postoperative infarction
Trial locations and contacts
1 site in 1 country.
About this study
Lung cancer remains the world's leading cancer in terms of morbidity and mortality, with more than 20 million new cases and 9.7 million deaths annually. Despite improvements in surgical techniques and medical care, the number of elderly people undergoing surgery is gradually increasing, so there are an increasing number of complications following lung resection. Postoperative cerebral infarction is a relatively rare but devastating complication that places a heavy burden on patients and families. The incidence of postoperative cerebral infarction in patients after thoracic surgery has been reported to be 0.6-1.1%. There is a risk of postoperative cerebral infarction after lung cancer surgery, and the results of a few studies have shown that postoperative cerebral infarction is related to old age, male, hypertension, hyperlipidemia, and lobectomy factors, but the pathogenesis of the occurrence of cerebral infarction has not been clearly proved for the time being, and so these risk factors cannot be taken as the direct cause of cerebral infarction. Therefore, we need to further explore the factors leading to cerebral infarction after lung cancer surgery. If we can further prove that some of the risk factors are related to the causes of cerebral infarction after lung cancer surgery, we can make corresponding strategies in the perioperative period to improve the safety of surgery and reduce the incidence of cerebral infarction in the postoperative period.
- Being tested
- non-intervention
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
non-interventionOther
non-intervention
| Study group | Role | What they receive |
|---|---|---|
| Postoperative cerebral infarction | Not described Receives: Other: non-intervention | |
| No postoperative cerebral infarction | Not described Receives: Other: non-intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysing independent risk factors for cerebral infarction after pneumonectomy
Clinical trial data were entered into Excel for recording information and subsequently converted to SPSS for statistical analysis. Descriptive statistics of the named data were expressed as absolute numbers and percentages according to each patient.
Clinical characteristics of patients who developed cerebral infarction after surgery were retrospectively compared with those of patients who underwent pneumonectomy without cerebral infarction. Continuous data were expressed as median and interquartile range, and categorical data were expressed as frequencies and percentages. Independent risk factors for developing cerebral infarction after pneumonectomy were analysed using univariate and multivariate logistic regression.
Measured: 5min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2025
- Study start1 Apr 2025
- Primary completion1 Oct 2025 (estimated)
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Lung Cancer, Non-Small CellStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xinghua Cheng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Xinghua Cheng, Shanghai Chest Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06942845
- Sponsor's protocol ID
- postoperative cerebral infarct
- Status last verified
- Apr 2025
- First submitted
- 17 Apr 2025
- Last updated
- 24 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Nishizawa N, Okawara M, Mori M, Fujino Y, Matsuda S, Fushimi K, Tanaka F. Postoperative cerebral infarction risk is related to lobectomy site in lung cancer: a retrospective cohort study of nationwide data in Japan. BMJ Open Respir Res. 2022 Jul;9(1):e001327. doi: 10.1136/bmjresp-2022-001327.
PubMed 35868837Matsumoto K, Sato S, Okumura M, Niwa H, Hida Y, Kaga K, Date H, Nakajima J, Usuda J, Suzuki M, Souma T, Tsuchida M, Miyata Y, Nagayasu T. Frequency of cerebral infarction after pulmonary resection: a multicenter, retrospective study in Japan. Surg Today. 2018 May;48(5):571-572. doi: 10.1007/s00595-017-1620-9. Epub 2018 Jan 11. No abstract available.
PubMed 29327086Gao S, Zhou Y, Yang R, Du C, Wu Y. Risk factors for postoperative cerebral infarction in patients after lung resection: a single-center case-control study. J Thorac Dis. 2023 Feb 28;15(2):376-385. doi: 10.21037/jtd-22-1019. Epub 2023 Jan 16.
PubMed 36910048Hattori A, Takamochi K, Kitamura Y, Matsunaga T, Suzuki K, Oh S, Suzuki K. Risk factor analysis of cerebral infarction and clinicopathological characteristics of left upper pulmonary vein stump thrombus after lobectomy. Gen Thorac Cardiovasc Surg. 2019 Feb;67(2):247-253. doi: 10.1007/s11748-018-1017-8. Epub 2018 Sep 24.
PubMed 30251002Nojiri T, Inoue M, Takeuchi Y, Maeda H, Shintani Y, Sawabata N, Hamasaki T, Okumura M. Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes. Surg Today. 2015 Jun;45(6):740-5. doi: 10.1007/s00595-014-1032-z. Epub 2014 Sep 19.
PubMed 25236860
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study
- ClinicalTrials.gov ID
- NCT06942845
- Acronym / sponsor ID
- postoperative cerebral infarct
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Xinghua ChengUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 24 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung cancer remains the world's leading cancer in terms of morbidity and mortality, with more than 20 million new cases and 9.7 million deaths annually. Despite improvements in surgical techniques and medical care, the number of elderly people undergoing surgery is gradually increasing, so there are an increasing number of complications following lung resection. Postoperative cerebral infarction is a relatively rare but devastating complication that places a heavy burden on patients and families. The incidence of postoperative cerebral infarction in patients after thoracic surgery has been reported to be 0.6-1.1%. There is a risk of postoperative cerebral infarction after lung cancer surgery, and the results of a few studies have shown that postoperative cerebral infarction is related to old age, male, hypertension, hyperlipidemia, and lobectomy factors, but the pathogenesis of the occurrence of cerebral infarction has not been clearly proved for the time being, and so these risk factors cannot be taken as the direct cause of cerebral infarction. Therefore, we need to further explore the factors leading to cerebral infarction after lung cancer surgery. If we can further prove that some of the risk factors are related to the causes of cerebral infarction after lung cancer surgery, we can make corresponding strategies in the perioperative period to improve the safety of surgery and reduce the incidence of cerebral infarction in the postoperative period.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Postoperative cerebral infarction | – | Other: non-intervention |
| No postoperative cerebral infarction | – | Other: non-intervention |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 1. patients with postoperative cerebral infarction in the hospital during the same period of time as the case group 2. hospitalised surgical patients in the same period as the control group. 3. patients who underwent pneumonectomy for lung nodules as the reason for surgery.
Key inclusion criteria (1 listed)
- Postoperative cerebral infarction
Key exclusion criteria (1 listed)
- No postoperative infarction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| non-interventionnon-intervention | Other | No postoperative cerebral infarction, Postoperative cerebral infarction |
Primary outcome
Analysing independent risk factors for cerebral infarction after pneumonectomy
Time frame: 5min
Clinical trial data were entered into Excel for recording information and subsequently converted to SPSS for statistical analysis. Descriptive statistics of the named data were expressed as absolute numbers and percentages according to each patient. Clinical characteristics of patients who developed cerebral infarction after surgery were retrospectively compared with those of patients who underwent pneumonectomy without cerebral infarction. Continuous data were expressed as median and interquartile range, and categorical data were expressed as frequencies and percentages. Independent risk factors for developing cerebral infarction after pneumonectomy were analysed using univariate and multivariate logistic regression.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2025.
- Background: PubMed 35868837Nishizawa N, Okawara M, Mori M, Fujino Y, Matsuda S, Fushimi K, Tanaka F. Postoperative cerebral infarction risk is related to lobectomy site in lung cancer: a retrospective cohort study of nationwide data in Japan. BMJ Open Respir Res. 2022 Jul;9(1):e001327. doi: 10.1136/bmjresp-2022-001327.
- Background: PubMed 29327086Matsumoto K, Sato S, Okumura M, Niwa H, Hida Y, Kaga K, Date H, Nakajima J, Usuda J, Suzuki M, Souma T, Tsuchida M, Miyata Y, Nagayasu T. Frequency of cerebral infarction after pulmonary resection: a multicenter, retrospective study in Japan. Surg Today. 2018 May;48(5):571-572. doi: 10.1007/s00595-017-1620-9. Epub 2018 Jan 11. No abstract available.
- Background: PubMed 36910048Gao S, Zhou Y, Yang R, Du C, Wu Y. Risk factors for postoperative cerebral infarction in patients after lung resection: a single-center case-control study. J Thorac Dis. 2023 Feb 28;15(2):376-385. doi: 10.21037/jtd-22-1019. Epub 2023 Jan 16.
- Background: PubMed 30251002Hattori A, Takamochi K, Kitamura Y, Matsunaga T, Suzuki K, Oh S, Suzuki K. Risk factor analysis of cerebral infarction and clinicopathological characteristics of left upper pulmonary vein stump thrombus after lobectomy. Gen Thorac Cardiovasc Surg. 2019 Feb;67(2):247-253. doi: 10.1007/s11748-018-1017-8. Epub 2018 Sep 24.
- Background: PubMed 25236860Nojiri T, Inoue M, Takeuchi Y, Maeda H, Shintani Y, Sawabata N, Hamasaki T, Okumura M. Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes. Surg Today. 2015 Jun;45(6):740-5. doi: 10.1007/s00595-014-1032-z. Epub 2014 Sep 19.
- Individual participant dataSharing planned: Undecided
Related trials for Lung Cancer, Non-Small Cell
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, Non-Small Cell and Postoperative Cerebral Infarction, run by Xinghua Cheng at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysing independent risk factors for cerebral infarction after pneumonectomy (time frame: 5min). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06942845, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2025.